A Multicenter, Single Arm, Post Marketing Surveillance Study to Monitor the Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects 2 Years of Age and Older in the Philippines
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions
- Sponsors Novartis
- 30 Nov 2016 Status changed from suspended to withdrawn prior to enrolment.
- 05 Jun 2013 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
- 09 Jan 2013 Planned initiation date changed from 1 Dec 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.